DMTK News and Press, DermTech Inc From 05/14/24

- Average selling price (ASP) for the DermTech Melanoma Test (DMT) increased 24 percent year-over-year - Test revenue increased 7 percent versus the first quarter of 2023 DermTech, Inc. (NASDAQ: DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a no...

AlloVir Inc. (ALVR) is expected to report $-0.16 for Q1 2024 Inter & Co. Inc. (INTR) is expected to report $0.08 for Q1 2024 Array Technologies Inc. (ARRY) is expected to report $-0.06 for Q1 2024 Sphere 3D Corp. (ANY) is expected to report $-0.23 for Q1 2024 Alpine Immune Sci...

Resideo Technologies Inc. (REZI) is expected to report $0.33 for Q1 2024 Schneider National Inc. (SNDR) is expected to report $0.13 for Q1 2024 Murphy Oil Corporation (MUR) is expected to report $0.82 for Q1 2024 Astronics Corp. - Class B (ATROB) is expected to report for Q1 2024 ...

2024-04-18 16:54:40 ET More on DermTech DermTech, Inc. (DMTK) Q4 2023 Earnings Call Transcript DermTech GAAP EPS of -$0.56 in-line, revenue of $3.92M misses by $0.11M DermTech Q4 2023 Earnings Preview Seeking Alpha’s Quant Rating on DermTech Hi...

DermTech, Inc. (NASDAQ: DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today announced the presentation of two research abstracts at the 2024 American Academy of Dermatology (AAD) Annual Meeting, taking place March 8th-12th i...

A look at the top 10 most actives in the United States Jaguar Health Inc. (JAGX) rose 44.2% to $0.0851 on volume of 271,253,038 shares Fisker Inc. Class A (FSR) fell 27.2% to $0.53 on volume of 253,915,529 shares Direxion Daily Semiconductor Bear 3X Shares (SOXS) fell 12.5% to $3.325 on v...

Evolv Technologies Holdings Inc. (EVLV) is expected to report $-0.14 for Q4 2023 The Lion Electric Company (LEV) is expected to report $-0.1 for Q4 2023 Fisker Inc. Class A (FSR) is expected to report $-0.2 for Q4 2023 Y-mAbs Therapeutics Inc. (YMAB) is expected to report $-0.19 for Q...

DermTech, Inc. (NASDAQ: DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, will host a conference call and webcast on Thursday, February 29, 2024 at 5:00 p.m. Eastern Time (ET) to discuss the Company's fourth-quarter 2023 operati...

2024-01-31 17:32:28 ET More on DermTech DermTech, Inc. (DMTK) Q3 2023 Earnings Call Transcript DermTech study finds melanoma test effective for all skin types DermTech stock rallies 18% on positive study for melanoma test Seeking Alpha’s Quant Rating o...

- Ongoing emphasis on growing revenue for the DermTech Melanoma Test (DMT) - Approximately $40 million in total operating expense reductions compared to fiscal 2022 resulting from all restructuring actions DermTech, Inc. (NASDAQ: DMTK) (DermTech or the Company), a leader in pr...